Scott S Graves1, David W Mathes2,3, Rainer Storb1,4. 1. Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1-100, Seattle, WA, U.S.A. 2. Department of Plastic Surgery, University of Colorado, Aurora, CO. 3. Plastic Surgery Service VA, Eastern Care System, Denver, CO. 4. University of Washington School of Medicine, Seattle, WA, U.S.A.
Abstract
BACKGROUND: The application of hematopoietic cell transplantation for induction of immune tolerance has been limited by toxicities associated with conditioning regimens and to graft-versus-host disease (GVHD). Decades of animal studies have culminated into sufficient control of these two problems, making immune tolerance a viable alternative to life-long application of immunosuppressive drugs to prevent allograft rejection. METHODS: Studies in mice have paved the way for the application of HCT with limited toxicity in large animal models. Resultant studies in the pig, dog, and ultimately the nonhuman primate have led to appropriate methods for achieving nonmyeloablative irradiation protocols, dose, and timing of post-grafting immunosuppressive drugs, monoclonal antibody therapy, and biologicals for costimulatory molecule blockade. The genetics field has been extensively evaluated in appreciation of the ultimate need to obtain organs from MHC-mismatched unrelated donors. RESULTS: Nonmyeloablative conditioning regimens have been shown to be successful in inducing immune tolerance across all three animal models. Postgrafting immunosuppression is also important in assuring sustained donor hematopoiesis for tolerance. Donor chimerism need not be permanent to establish stable engraftment of donor organs, thereby essentially eliminating the risk of GVHD. Using nonmyeloablative HCT with monoclonal antibody immunosuppression, the kidney has been successfully transplanted in MHC-mismatched nonhuman primates. CONCLUSIONS: Nonmyeloablative HCT for the establishment of temporary mixed chimerism has led to the establishment of stable tolerance against solid organ allografts in large animal models. The kidney, considered a tolerogenic organ, has been successfully transplanted in the clinic. Other organs such as heart, lung, and vascularized composite allografts (face and hands), remain distant possibilities. Further study in large animal models will be required to improve tolerance against these organs before success can be attained in the clinic.
BACKGROUND: The application of hematopoietic cell transplantation for induction of immune tolerance has been limited by toxicities associated with conditioning regimens and to graft-versus-host disease (GVHD). Decades of animal studies have culminated into sufficient control of these two problems, making immune tolerance a viable alternative to life-long application of immunosuppressive drugs to prevent allograft rejection. METHODS: Studies in mice have paved the way for the application of HCT with limited toxicity in large animal models. Resultant studies in the pig, dog, and ultimately the nonhuman primate have led to appropriate methods for achieving nonmyeloablative irradiation protocols, dose, and timing of post-grafting immunosuppressive drugs, monoclonal antibody therapy, and biologicals for costimulatory molecule blockade. The genetics field has been extensively evaluated in appreciation of the ultimate need to obtain organs from MHC-mismatched unrelated donors. RESULTS: Nonmyeloablative conditioning regimens have been shown to be successful in inducing immune tolerance across all three animal models. Postgrafting immunosuppression is also important in assuring sustained donor hematopoiesis for tolerance. Donor chimerism need not be permanent to establish stable engraftment of donor organs, thereby essentially eliminating the risk of GVHD. Using nonmyeloablative HCT with monoclonal antibody immunosuppression, the kidney has been successfully transplanted in MHC-mismatched nonhuman primates. CONCLUSIONS: Nonmyeloablative HCT for the establishment of temporary mixed chimerism has led to the establishment of stable tolerance against solid organ allografts in large animal models. The kidney, considered a tolerogenic organ, has been successfully transplanted in the clinic. Other organs such as heart, lung, and vascularized composite allografts (face and hands), remain distant possibilities. Further study in large animal models will be required to improve tolerance against these organs before success can be attained in the clinic.
Entities:
Keywords:
Tolerance; hematopoietic cell transplantation; large animal model; organ transplantation; preclinical
Authors: D Eastwood; L Findlay; S Poole; C Bird; M Wadhwa; M Moore; C Burns; R Thorpe; R Stebbings Journal: Br J Pharmacol Date: 2010-10 Impact factor: 8.739
Authors: K Shinoda; T Akiyoshi; C M Chase; E A Farkash; D K Ndishabandi; C M Raczek; D P Sebastian; P Della Pelle; P S Russell; J C Madsen; R B Colvin; A Alessandrini Journal: Am J Transplant Date: 2014-08-25 Impact factor: 8.086
Authors: D Fradelizi; G Mahouy; C de Riberolles; Y Lecompte; P Alhomme; M C Douard; G Chotin; H Martelli; F Daburon; M Vaiman Journal: Transplantation Date: 1981-05 Impact factor: 4.939
Authors: Michael Tillson; Glenn P Niemeyer; Janet A Welch; William Brawner; Steven F Swaim; Pat Rynders; Stephen D Lenz; Bridget Dean; Clinton D Lothrop Journal: Exp Hematol Date: 2006-12 Impact factor: 3.084
Authors: R Storb; P L Weiden; K M Sullivan; F R Appelbaum; P Beatty; C D Buckner; R A Clift; K C Doney; J Hansen; P J Martin Journal: Blood Date: 1987-07 Impact factor: 22.113